Palbociclib in solid tumor patients with genomic alterations in the cyclin D-CDK4/6-INK4a-Rb pathway: Results from NCI-COG pediatric MATCH trial Arm I (APEC1621I). This is an ASCO Meeting Abstract ...

This residue is replaced in CDK4 by Thr89, whose shorter side-chain cannot form similar bonds, explaining the relative selectivity of the inhibitors for CDK2. Our results provide a generally ...

The amount of CDK4/6-targeting treatment options available for patients with HR-positive breast cancer allows providers to personalize treatment. While there are multiple treatment paths available for ...

Department of Chemistry, University of Cape Town, Rondebosch ,7701 Cape Town, South Africa Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Observatory, 7925 Cape Town, ...

Breast cancer is a leading cause of mortality worldwide. Pharmacological inhibitors of cyclin-dependent kinases (CDK) 4 and 6 (CDK4/6i) inhibit breast cancer growth by inducing a senescent-like state.

In this issue, Yi and colleagues demonstrate therapeutic synergy for combined PARP and CDK4/6 inhibition and identify MYC status as a determinant of sensitivity to combined PARP and CDK4/6 inhibition ...

In early-stage estrogen receptor-positive (ER + ) breast cancer, resistance to endocrine therapy (ET) and CDK4/6 inhibitors (CDK4/6i) often involve a shift away from estrogen-driven proliferation. The ...

Panelists discuss how the EMERALD trial demonstrated elacestrant's efficacy in ESR1-mutated tumors, particularly in patients who had received CDK4/6 inhibitors for at least 12 months. This led to its ...

Cyclin-dependent kinase 4/6 inhibitors (CDK4/6is) combined with endocrine therapy (ET) are the standard of care in hormone receptor–positive/human epidermal growth factor receptor 2–negative ...

Preclinical data have shown that cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors can inhibit tumour growth and act synergistically with oestrogen receptor antagonists to overcome endocrine therapy ...

The FDA's decision to grant INX-315 fast track designation was based on preclinical data and interim data from the ongoing phase 1/2 INX-315-01 trial. The US Food and Drug Administration (FDA) has ...